Prevalence of metabolic dysfunction-associated steatotic liver disease and steatohepatitis in Türkiye: A forensic autopsy study

被引:2
|
作者
Ergenc, Ilkay [1 ,2 ]
Kara, Erdogan [3 ]
Yilmaz, Muhammed Emre [3 ]
Demirtas, Coskun Ozer [1 ]
Keklikkiran, Caglayan [4 ]
Das, Taner [3 ]
Buyuk, Yalcin [3 ,5 ]
Celikel, Cigdem [6 ]
Asliyuksek, Hizir [3 ]
Yilmaz, Yusuf [1 ,4 ]
机构
[1] Marmara Univ, Sch Med, Dept Gastroenterol, Istanbul, Turkiye
[2] Kings Coll Hosp London, Inst Liver Studies, London, England
[3] Minist Justice, Council Forens Med, Istanbul, Turkiye
[4] Recep Tayyip Erdogan Univ, Sch Med, Dept Gastroenterol, Rize, Turkiye
[5] Istanbul Univ Cerrahpasa, Inst Legal Med & Forens Sci, Istanbul, Turkiye
[6] Marmara Univ, Sch Med, Dept Pathol, Istanbul, Turkiye
关键词
MASLD; Steatohepatitis; Liver; Steatosis; Autopsy; Histology; FATTY LIVER; ULTRASONOGRAPHY; TURKEY; RISK;
D O I
10.1016/j.heliyon.2024.e34915
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background and aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global epidemic in T & uuml;rkiye and worldwide. The aim of this study was to evaluate the prevalence and predictors of MASLD and steatohepatitis among adults who died of unnatural causes including sudden death and non-burn trauma. Method: We conducted a prospective review of all consecutive adult forensic autopsies for natural (sudden unexpected) and non-natural (Suicidal, homicidal and accidental) suspicious deaths carried out at the Istanbul Council of Forensic Medicine from February to May 2022. Four wedge biopsies were extracted from sagittal sectioned liver specimens. A liver pathologist with 20 years of experience examined each case for steatosis, ballooning, inflammation, and fibrosis. Results: Among 1797 autopsies, 62 met inclusion criteria. Overall, 43.3 % (n = 26) of autopsies showed evidence of steatotic liver disease, with a distribution of steatosis severity as: Grade I (28.3 %), Grade II (6.6 %), and Grade III (8.3 %). All these cases met at least one cardiometabolic criteria and diagnosed with MASLD. Ballooning was observed in 20.0 % of cases (5 cases grades 1 and 7 cases grade 2), and Inflammation was present in 51.7 % (9 cases with grade 0-1, 12 with 1-2, 7 with 2-3, and 3 with 5-6). Notably, 46.1 % (n = 12) of MASLD cases and 20.0 % (n = 12) of all cases were diagnosed with steatohepatitis, with three cases exhibiting delicate perisinusoidal fibrosis and one case showing portal fibrosis. Conclusion: The histopathological findings from this autopsy study confirmed the markedly high prevalence of MASLD and steatohepatitis within the general adult population, highlighting the concerning burden of steatotic liver disease in T & uuml;rkiye.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Metabolic Dysfunction-Associated Steatotic Liver Disease: An Overview of Pharmacotherapy
    El Hussein, Mohamed
    Favell, Daniel
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2025, 21 (02):
  • [32] Vitamin E in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Kountouras, Jannis
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2025, 40 (02) : 551 - 552
  • [33] Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease
    Ni, Keying
    Meng, Lina
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (07)
  • [34] Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease
    Cherubini, Alessandro
    Della Torre, Sara
    Pelusi, Serena
    Valenti, Luca
    TRENDS IN MOLECULAR MEDICINE, 2024, 30 (12) : 1126 - 1136
  • [35] Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Scarpellini, Emidio
    Scarcella, Marialaura
    Tack, Jan F.
    Scarlata, Giuseppe Guido Maria
    Zanetti, Michela
    Abenavoli, Ludovico
    ANTIOXIDANTS, 2024, 13 (11)
  • [36] Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Rodriguez, Luis A.
    Schmittdiel, Julie A.
    Liu, Liyan
    Macdonald, Brock A.
    Balasubramanian, Sreepriya
    Chai, Krisna P.
    Seo, Suk I.
    Mukhtar, Nizar
    Levin, Theodore R.
    Saxena, Varun
    JAMA NETWORK OPEN, 2024, 7 (07) : e2421019
  • [37] Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
    Sandireddy, Reddemma
    Sakthivel, Suganya
    Gupta, Priyanka
    Behari, Jatin
    Tripathi, Madhulika
    Singh, Brijesh Kumar
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [38] Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
    Lee, Hyeok-Hee
    Lee, Han Ah
    Kim, Eun-Jin
    Kim, Hwi Young
    Kim, Hyeon Chang
    Ahn, Sang Hoon
    Lee, Hokyou
    Kim, Seung Up
    GUT, 2024, 73 (03) : 533 - 540
  • [39] Progress in the Study of Animal Models of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Fu, Yu
    Hua, Yuxin
    Alam, Naqash
    Liu, Enqi
    NUTRIENTS, 2024, 16 (18)
  • [40] Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
    Noureddin, Nabil
    Copur-Dahi, Nedret
    Loomba, Rohit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 : S41 - S51